Home » Biotech Research and Development Expenditures Up 20%
Biotech Research and Development Expenditures Up 20%
Looking to accelerate drug candidates through clinical trials, biotech firms have boosted overall research and development (R&D) expenditures 20% in just a year, according to research and consulting firm GlobalData. In its new report, GlobalData compares the competitive position of 15 innovative mid-cap biotech companies on 20 financial metrics, finding that for the peer group, R&D spend for Q3 2012 reached $746.8M, climbing from $621.1M in Q3 2011.
“Biotech companies are becoming increasingly more successful at developing innovative therapies,” says Adam Dion, GlobalData’s Analyst covering Healthcare Industry Dynamics. “However, our research has found that the high cost of bringing these therapies to market continues to erode corporate profitability.” Dion explains that oncology is a main focus of biotech R&D activities, “which is driving peer group R&D expenses higher.”
Among its peers, Regeneron reported the highest R&D spend for Q3 2012, with an outlay of $158M. According to the report, Regeneron’s R&D spend has increased steadily each quarter since Q3 2011, when the total stood at $128M.
However some firms are spending less. In terms of percentages, ViroPharma displayed the biggest year-to-year drop in R&D expenditures, reporting that the company’s R&D spending plummeted year-to-year, from $22.9M in Q3 2011 to $16.5M in Q3 2012, a drop of 28%. GobalData’s report blames the decrease on the Food and Drug Administration’s suspension of clinical trials of Cinryze, the company’s flagship product.
“The FDA put a hold on two of the company’s Phase II clinical studies when trials revealed elevated antibody levels detected in the treatment arm of the study,” notes Dion. “These concerns have since been addressed and, with FDA approval, the firm resumed the trials in September of last year.”
Aragon Purchased For $650M+From USA Today
Johnson & Johnson has agreed to buy Aragon Pharmaceuticals for at least $650 million in cash.
ASME BPE Certifies MaxPure Stainless-Steel Fittings
TEK Stainless Piping Products announces certification of MaxPure, EGMO’S stainless-steel fitting product line for bioprocessing industry
Supreme Court Rules Against 'pay-to-delay'From Economic Times
Big pharma companies lose in Supreme Court's 'pay-to-delay' decision.
BioScrip Acquires CarePoint for $223 MillionFrom Bloomberg Businessweek
BioScrip Inc. plans to expand its drug infusion business with a new acquisition of CarePoint for $223 million.
Endress+Hauser Offers Online Thermowell Sizing Calculator
Free, online thermowell calculation tool compliant with new ASME PTC 19.3 TW-2010 standards simplifies engineer work
Supreme Court DNA Ruling Could Hurt Biotech IndustryFrom The Denver Post Politics
Critics said the ruling would discourage other companies and financial backers from investing in more genetic sequencing research
Supreme Court Says No to Patenting Human GenesFrom The Scientist
The Court unanimously ruled that isolated sequences of human DNA are not eligible for patent protection, but artificial sequences can be patented
All-new Pharma EXPO Debuts in November 2014
Co-located with PACK-EXPO International, ISPE Pharma EXPO will be held in Chicago
Canadian Health Authority Accepts Use of Roche's Rapid Mycoplasma Detection TestFrom Roche
Roche’s Rapid Mycoplasma Detection Test MycoTOOL Receives Acceptance from Canadian Authorities for Release Testing of Biopharmaceutical Roche Product
Over 200 Cardiovascular Disease Drugs in DevelopmentFrom Drug Store News
According a recent report, 215 drugs are now under development for heart disease and stroke.
- All news »